| Budget Amount *help |
¥2,760,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥60,000)
Fiscal Year 2007: ¥260,000 (Direct Cost: ¥200,000、Indirect Cost: ¥60,000)
Fiscal Year 2006: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2005: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2004: ¥1,100,000 (Direct Cost: ¥1,100,000)
|
|---|
| Research Abstract |
Type I Interferon is widely used for advanced renal cell carcinoma (RCC). In some uses without metastasis, interferon is used for adjuvant situation. However interferon is expensive and appropriate usage is required. Here, we examined expression of interferon receptors in cases with RCC.
Type I interferon receptor is dimeric and composed of INFAR1 and INFAR2. We performed RT-PCR in peripheral blood, renal tumor, and non-neoplastic renal tissue of 19 RCC cases and one renal angiomyolipoma case.
RT-PCR showed significant correlation of expression of INFAR1 in peripheral blood, renal tumor, and non-neoplastic renal tissue. Also, there was a significant correlation of expression of IFNAR2 in peripheral blood, renal tumor, and non-neoplastic renal tissue.
However, there was no correlation of the expression of receptors with clinical parameters including LDH, ALP, Hemoglobin, tumor grade, and tumor stage.
These data suggest that expression of receptors in peripheral blood reflects in tumor tissue and that we may examine only the expression of peripheral blood. Also, no correlation with clinical parameters suggests the expression of receptors might be a new prognostic marker.
|
